Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Roswell Park Cancer Institute
University of Virginia
University of Virginia
Abramson Cancer Center at Penn Medicine
University of Maryland, Baltimore
Mayo Clinic
University of Virginia
Memorial Sloan Kettering Cancer Center
University of Virginia
University of Virginia
University of Virginia
University of Virginia
University of Virginia
University of Virginia
University of Southern California
University of Southern California
University of Southern California
University of Southern California
University of Southern California
University of Southern California
Memorial Sloan Kettering Cancer Center
The University of Texas Medical Branch, Galveston